Boston Scientific CorporationBSX

Where BSX's Net Debt / EBITDA sits inside its own 10-year distribution, with the yearly high, low and average.

$45.05+2.07 (+4.82%)Previous close
NYSEHealthcare

BSX Net Debt / EBITDA: current value, 10-year range and year-by-year history

Net Debt / EBITDA History

Historically priceyAbove avgAround avgBelow avgHistorically cheap
BSX Net Debt / EBITDA historyBSX Net Debt / EBITDA from Sep 2023 to Jun 2026: low 1.68, high 2.73, latest 2.13.1.61.92.212.512.82Sep 23Mar 24Sep 24Jun 25Dec 25Jun 26med 2.34

BSX Net Debt / EBITDA by year

Yearly range of BSX’s net debt / ebitda from 2016 to 2026. Over the full period it ranged from 1.7 to 15.4, averaging 3.6.

BSX Net Debt / EBITDA — yearly low, average, high and year-end values
YearLowAverageHighYear-end
20261.71.92.12.1
20252.02.32.62.0
20242.22.42.72.7
20232.52.83.12.5
20223.03.33.63.0
20212.83.44.53.0
20205.35.76.15.7
20193.34.04.64.6
20182.62.72.72.7
20172.73.44.82.7
20165.510.515.45.5

Get notified when BSX Net Debt / EBITDA crosses a threshold

Free — one alert setup, notifications by push, Telegram, or Discord.

How many years of operating earnings it would take to pay off the company's net debt. The most common leverage ratio — higher means more financial risk and less flexibility.

Formula(Total Debt − Cash) / EBITDA
Full guide
How to read this chart

Watch the trend more than the level. Declining ratio = deleveraging, growing financial flexibility. Rising ratio = increasing leverage, which constrains dividends, buybacks, and future investment.

Key caveats
  • Sector context is essential: 3× is aggressive for a consumer brand but normal for a regulated utility. Always compare to sector peers.
  • Large acquisitions spike the ratio temporarily — check whether the integration plan credibly drives paydown.
Pro — up to 30-year history

Unlock 10y, 15y, 20y, and 30y history with peer comparison and CSV export.